Share of biopharma M&A deals worldwide with upfront payment 2017-21, by therapy area
Between 2017 and 2021, around 50 percent of all immunomodulators biopharma M&A deals worldwide involved upfront payments, while only 21 percent of all oncology biopharma deals involved such payments. This statistic illustrates the number of deals in the biopharmaceutical industry with upfront payment components in 2017-2021, by therapy area.